Clinical Phenotype of HLA B44 Patients in a Rheumatology Outpatient Clinic Favors Peripheral Arthropathies
The genetic background of HLA-B*27 in spondyloarthritis is known, and the search for another gene with similar role is ongoing. We wanted to investigate clinical presentations of HLA-B*44 patients in rheumatology practice. A cross-sectional retrospective study of 303 HLA-B*44 adult patients from the...
Gespeichert in:
Veröffentlicht in: | Journal of clinical medicine 2024-09, Vol.13 (18), p.5440 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 18 |
container_start_page | 5440 |
container_title | Journal of clinical medicine |
container_volume | 13 |
creator | Aljinović, Jure Šošo, Daniela Petrić, Marin Perković, Dijana Marasović Krstulović, Daniela Kero, Darko Marinović, Ivanka |
description | The genetic background of HLA-B*27 in spondyloarthritis is known, and the search for another gene with similar role is ongoing. We wanted to investigate clinical presentations of HLA-B*44 patients in rheumatology practice.
A cross-sectional retrospective study of 303 HLA-B*44 adult patients from the outpatient rheumatology clinic from 5/2018-5/2024. Clinical phenotype, confirmed or excluded rheumatic diagnosis, therapy used, and data on HLA A, B, and DR alleles inherited with B*44 were analyzed.
A female predominance of 2.79:1 was noted. A total of 150 [49.5%] patients were referred due to peripheral joint pain, 77 [25.4%] due to combined spine and peripheral joint pain or spine alone (57 [18.8%]). A total of 19 [6.3%] patients had no symptoms of the musculoskeletal system. Statistically significant peripheral joint affection was proved in females but not in males (
= 0.04). A total of 121 [40%] patients from B*44 group had established rheumatic disease, with the rest being excluded or under observation. The most common working diagnoses were polyarthritis (32 [10.5%]) and mono-oligoarthritis (14 [4.6%]). A second allele in addition to HLA B*44 showed a similar frequency to the general population. Patients with HLA B*44/44 and B*27/44 genotypes were at the most risk for having definitive rheumatic disease (>60%). Conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) were used in 38.6% of patients, non-steroidal anti-inflammatory drugs were used in 31.6% of patients, biologic DMARDs were used in 8.9% of patients, and corticosteroids were used in 7.3% of patients.
The most common presentation in HLA-B*44 patients is peripheral joint affection. Most patients with HLA-B*27/44 and B*44/44 genotypes had definitive rheumatic disease. B*44 homozygosity or B*27/44 might be risk factors for arthritis development. |
doi_str_mv | 10.3390/jcm13185440 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11432423</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A811440843</galeid><sourcerecordid>A811440843</sourcerecordid><originalsourceid>FETCH-LOGICAL-c328t-d80c05f45c0c89497fed91ce786c6ebb8d6659c4cb2544cbc1a02d593940409b3</originalsourceid><addsrcrecordid>eNptkt9rFDEQx4MottQ--S4BXwS5ml-7mzzJedhWOOgh-hyy2dnbHLvJmuwW7r8316v1KiYPCZnPfGe-YRB6S8kV54p82tmBcioLIcgLdM5IVS0Il_zlyf0MXaa0I3lJKRitXqMzrjgvFavO0W7VO--s6fGmAx-m_Qg4tPh2vcRfhMAbMznwU8LOY4O_dzAPZgp92O7x3TyNxyg-auBrcx9iwhuIbuwgZs1lnLoYMtY5SG_Qq9b0CS4fzwv08_rrj9XtYn138221XC8sZ3JaNJJYUrSisMRKJVTVQqOohUqWtoS6lk1ZFsoKW7Ps2taWGsKaQnEliCCq5hfo81F3nOsBGps7zL3oMbrBxL0OxunnEe86vQ33mlLBmWA8K3x4VIjh1wxp0oNLFvreeAhz0pxSoighrMro-3_QXZijz_4eqIIJqoq_1Nb0oJ1vQy5sD6J6KXNZQaQ4lL36D5V3A4OzwUPr8vuzhI_HBBtDShHaJ5OU6MN46JPxyPS70395Yv8MA_8Nc9iz1g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3110524195</pqid></control><display><type>article</type><title>Clinical Phenotype of HLA B44 Patients in a Rheumatology Outpatient Clinic Favors Peripheral Arthropathies</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Aljinović, Jure ; Šošo, Daniela ; Petrić, Marin ; Perković, Dijana ; Marasović Krstulović, Daniela ; Kero, Darko ; Marinović, Ivanka</creator><creatorcontrib>Aljinović, Jure ; Šošo, Daniela ; Petrić, Marin ; Perković, Dijana ; Marasović Krstulović, Daniela ; Kero, Darko ; Marinović, Ivanka</creatorcontrib><description>The genetic background of HLA-B*27 in spondyloarthritis is known, and the search for another gene with similar role is ongoing. We wanted to investigate clinical presentations of HLA-B*44 patients in rheumatology practice.
A cross-sectional retrospective study of 303 HLA-B*44 adult patients from the outpatient rheumatology clinic from 5/2018-5/2024. Clinical phenotype, confirmed or excluded rheumatic diagnosis, therapy used, and data on HLA A, B, and DR alleles inherited with B*44 were analyzed.
A female predominance of 2.79:1 was noted. A total of 150 [49.5%] patients were referred due to peripheral joint pain, 77 [25.4%] due to combined spine and peripheral joint pain or spine alone (57 [18.8%]). A total of 19 [6.3%] patients had no symptoms of the musculoskeletal system. Statistically significant peripheral joint affection was proved in females but not in males (
= 0.04). A total of 121 [40%] patients from B*44 group had established rheumatic disease, with the rest being excluded or under observation. The most common working diagnoses were polyarthritis (32 [10.5%]) and mono-oligoarthritis (14 [4.6%]). A second allele in addition to HLA B*44 showed a similar frequency to the general population. Patients with HLA B*44/44 and B*27/44 genotypes were at the most risk for having definitive rheumatic disease (>60%). Conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) were used in 38.6% of patients, non-steroidal anti-inflammatory drugs were used in 31.6% of patients, biologic DMARDs were used in 8.9% of patients, and corticosteroids were used in 7.3% of patients.
The most common presentation in HLA-B*44 patients is peripheral joint affection. Most patients with HLA-B*27/44 and B*44/44 genotypes had definitive rheumatic disease. B*44 homozygosity or B*27/44 might be risk factors for arthritis development.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm13185440</identifier><identifier>PMID: 39336927</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antigens ; Care and treatment ; Chi-square test ; Classification ; Crohn's disease ; Diagnosis ; Females ; Genetic aspects ; Genotype & phenotype ; Health aspects ; Histocompatibility antigens ; HLA histocompatibility antigens ; Inflammatory bowel disease ; Osteoarthritis ; Outpatient care facilities ; Pain ; Patients ; Physiological aspects ; Rheumatic diseases ; Rheumatoid arthritis ; Rheumatology ; Spondyloarthropathies ; Statistical analysis ; Statistical significance</subject><ispartof>Journal of clinical medicine, 2024-09, Vol.13 (18), p.5440</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c328t-d80c05f45c0c89497fed91ce786c6ebb8d6659c4cb2544cbc1a02d593940409b3</cites><orcidid>0000-0002-8091-6347 ; 0000-0001-9546-3777</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11432423/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11432423/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39336927$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aljinović, Jure</creatorcontrib><creatorcontrib>Šošo, Daniela</creatorcontrib><creatorcontrib>Petrić, Marin</creatorcontrib><creatorcontrib>Perković, Dijana</creatorcontrib><creatorcontrib>Marasović Krstulović, Daniela</creatorcontrib><creatorcontrib>Kero, Darko</creatorcontrib><creatorcontrib>Marinović, Ivanka</creatorcontrib><title>Clinical Phenotype of HLA B44 Patients in a Rheumatology Outpatient Clinic Favors Peripheral Arthropathies</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>The genetic background of HLA-B*27 in spondyloarthritis is known, and the search for another gene with similar role is ongoing. We wanted to investigate clinical presentations of HLA-B*44 patients in rheumatology practice.
A cross-sectional retrospective study of 303 HLA-B*44 adult patients from the outpatient rheumatology clinic from 5/2018-5/2024. Clinical phenotype, confirmed or excluded rheumatic diagnosis, therapy used, and data on HLA A, B, and DR alleles inherited with B*44 were analyzed.
A female predominance of 2.79:1 was noted. A total of 150 [49.5%] patients were referred due to peripheral joint pain, 77 [25.4%] due to combined spine and peripheral joint pain or spine alone (57 [18.8%]). A total of 19 [6.3%] patients had no symptoms of the musculoskeletal system. Statistically significant peripheral joint affection was proved in females but not in males (
= 0.04). A total of 121 [40%] patients from B*44 group had established rheumatic disease, with the rest being excluded or under observation. The most common working diagnoses were polyarthritis (32 [10.5%]) and mono-oligoarthritis (14 [4.6%]). A second allele in addition to HLA B*44 showed a similar frequency to the general population. Patients with HLA B*44/44 and B*27/44 genotypes were at the most risk for having definitive rheumatic disease (>60%). Conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) were used in 38.6% of patients, non-steroidal anti-inflammatory drugs were used in 31.6% of patients, biologic DMARDs were used in 8.9% of patients, and corticosteroids were used in 7.3% of patients.
The most common presentation in HLA-B*44 patients is peripheral joint affection. Most patients with HLA-B*27/44 and B*44/44 genotypes had definitive rheumatic disease. B*44 homozygosity or B*27/44 might be risk factors for arthritis development.</description><subject>Antigens</subject><subject>Care and treatment</subject><subject>Chi-square test</subject><subject>Classification</subject><subject>Crohn's disease</subject><subject>Diagnosis</subject><subject>Females</subject><subject>Genetic aspects</subject><subject>Genotype & phenotype</subject><subject>Health aspects</subject><subject>Histocompatibility antigens</subject><subject>HLA histocompatibility antigens</subject><subject>Inflammatory bowel disease</subject><subject>Osteoarthritis</subject><subject>Outpatient care facilities</subject><subject>Pain</subject><subject>Patients</subject><subject>Physiological aspects</subject><subject>Rheumatic diseases</subject><subject>Rheumatoid arthritis</subject><subject>Rheumatology</subject><subject>Spondyloarthropathies</subject><subject>Statistical analysis</subject><subject>Statistical significance</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptkt9rFDEQx4MottQ--S4BXwS5ml-7mzzJedhWOOgh-hyy2dnbHLvJmuwW7r8316v1KiYPCZnPfGe-YRB6S8kV54p82tmBcioLIcgLdM5IVS0Il_zlyf0MXaa0I3lJKRitXqMzrjgvFavO0W7VO--s6fGmAx-m_Qg4tPh2vcRfhMAbMznwU8LOY4O_dzAPZgp92O7x3TyNxyg-auBrcx9iwhuIbuwgZs1lnLoYMtY5SG_Qq9b0CS4fzwv08_rrj9XtYn138221XC8sZ3JaNJJYUrSisMRKJVTVQqOohUqWtoS6lk1ZFsoKW7Ps2taWGsKaQnEliCCq5hfo81F3nOsBGps7zL3oMbrBxL0OxunnEe86vQ33mlLBmWA8K3x4VIjh1wxp0oNLFvreeAhz0pxSoighrMro-3_QXZijz_4eqIIJqoq_1Nb0oJ1vQy5sD6J6KXNZQaQ4lL36D5V3A4OzwUPr8vuzhI_HBBtDShHaJ5OU6MN46JPxyPS70395Yv8MA_8Nc9iz1g</recordid><startdate>20240913</startdate><enddate>20240913</enddate><creator>Aljinović, Jure</creator><creator>Šošo, Daniela</creator><creator>Petrić, Marin</creator><creator>Perković, Dijana</creator><creator>Marasović Krstulović, Daniela</creator><creator>Kero, Darko</creator><creator>Marinović, Ivanka</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8091-6347</orcidid><orcidid>https://orcid.org/0000-0001-9546-3777</orcidid></search><sort><creationdate>20240913</creationdate><title>Clinical Phenotype of HLA B44 Patients in a Rheumatology Outpatient Clinic Favors Peripheral Arthropathies</title><author>Aljinović, Jure ; Šošo, Daniela ; Petrić, Marin ; Perković, Dijana ; Marasović Krstulović, Daniela ; Kero, Darko ; Marinović, Ivanka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c328t-d80c05f45c0c89497fed91ce786c6ebb8d6659c4cb2544cbc1a02d593940409b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antigens</topic><topic>Care and treatment</topic><topic>Chi-square test</topic><topic>Classification</topic><topic>Crohn's disease</topic><topic>Diagnosis</topic><topic>Females</topic><topic>Genetic aspects</topic><topic>Genotype & phenotype</topic><topic>Health aspects</topic><topic>Histocompatibility antigens</topic><topic>HLA histocompatibility antigens</topic><topic>Inflammatory bowel disease</topic><topic>Osteoarthritis</topic><topic>Outpatient care facilities</topic><topic>Pain</topic><topic>Patients</topic><topic>Physiological aspects</topic><topic>Rheumatic diseases</topic><topic>Rheumatoid arthritis</topic><topic>Rheumatology</topic><topic>Spondyloarthropathies</topic><topic>Statistical analysis</topic><topic>Statistical significance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aljinović, Jure</creatorcontrib><creatorcontrib>Šošo, Daniela</creatorcontrib><creatorcontrib>Petrić, Marin</creatorcontrib><creatorcontrib>Perković, Dijana</creatorcontrib><creatorcontrib>Marasović Krstulović, Daniela</creatorcontrib><creatorcontrib>Kero, Darko</creatorcontrib><creatorcontrib>Marinović, Ivanka</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aljinović, Jure</au><au>Šošo, Daniela</au><au>Petrić, Marin</au><au>Perković, Dijana</au><au>Marasović Krstulović, Daniela</au><au>Kero, Darko</au><au>Marinović, Ivanka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Phenotype of HLA B44 Patients in a Rheumatology Outpatient Clinic Favors Peripheral Arthropathies</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2024-09-13</date><risdate>2024</risdate><volume>13</volume><issue>18</issue><spage>5440</spage><pages>5440-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>The genetic background of HLA-B*27 in spondyloarthritis is known, and the search for another gene with similar role is ongoing. We wanted to investigate clinical presentations of HLA-B*44 patients in rheumatology practice.
A cross-sectional retrospective study of 303 HLA-B*44 adult patients from the outpatient rheumatology clinic from 5/2018-5/2024. Clinical phenotype, confirmed or excluded rheumatic diagnosis, therapy used, and data on HLA A, B, and DR alleles inherited with B*44 were analyzed.
A female predominance of 2.79:1 was noted. A total of 150 [49.5%] patients were referred due to peripheral joint pain, 77 [25.4%] due to combined spine and peripheral joint pain or spine alone (57 [18.8%]). A total of 19 [6.3%] patients had no symptoms of the musculoskeletal system. Statistically significant peripheral joint affection was proved in females but not in males (
= 0.04). A total of 121 [40%] patients from B*44 group had established rheumatic disease, with the rest being excluded or under observation. The most common working diagnoses were polyarthritis (32 [10.5%]) and mono-oligoarthritis (14 [4.6%]). A second allele in addition to HLA B*44 showed a similar frequency to the general population. Patients with HLA B*44/44 and B*27/44 genotypes were at the most risk for having definitive rheumatic disease (>60%). Conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) were used in 38.6% of patients, non-steroidal anti-inflammatory drugs were used in 31.6% of patients, biologic DMARDs were used in 8.9% of patients, and corticosteroids were used in 7.3% of patients.
The most common presentation in HLA-B*44 patients is peripheral joint affection. Most patients with HLA-B*27/44 and B*44/44 genotypes had definitive rheumatic disease. B*44 homozygosity or B*27/44 might be risk factors for arthritis development.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39336927</pmid><doi>10.3390/jcm13185440</doi><orcidid>https://orcid.org/0000-0002-8091-6347</orcidid><orcidid>https://orcid.org/0000-0001-9546-3777</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2077-0383 |
ispartof | Journal of clinical medicine, 2024-09, Vol.13 (18), p.5440 |
issn | 2077-0383 2077-0383 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11432423 |
source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Antigens Care and treatment Chi-square test Classification Crohn's disease Diagnosis Females Genetic aspects Genotype & phenotype Health aspects Histocompatibility antigens HLA histocompatibility antigens Inflammatory bowel disease Osteoarthritis Outpatient care facilities Pain Patients Physiological aspects Rheumatic diseases Rheumatoid arthritis Rheumatology Spondyloarthropathies Statistical analysis Statistical significance |
title | Clinical Phenotype of HLA B44 Patients in a Rheumatology Outpatient Clinic Favors Peripheral Arthropathies |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T00%3A38%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Phenotype%20of%20HLA%20B44%20Patients%20in%20a%20Rheumatology%20Outpatient%20Clinic%20Favors%20Peripheral%20Arthropathies&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Aljinovi%C4%87,%20Jure&rft.date=2024-09-13&rft.volume=13&rft.issue=18&rft.spage=5440&rft.pages=5440-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm13185440&rft_dat=%3Cgale_pubme%3EA811440843%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3110524195&rft_id=info:pmid/39336927&rft_galeid=A811440843&rfr_iscdi=true |